News

Hosted on MSN1mon
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...
pharmaphorum4d
Axsome bounces back as FDA clears depression drug
Shares in Axsome Therapeutics have rocketed on FDA approval ... to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week ...